Dendreon Corp. (DNDN)
-NasdaqGS 2.94 
0.01(0.34%) Oct 1, 4:00PM EDT|After Hours
:
2.95 0.01 (0.34%) Oct 1, 7:50PM EDT
| Prev Close: | 2.93 |
|---|
| Open: | 2.93 |
|---|
| Bid: | 2.88 x 1500 |
|---|
| Ask: | 3.19 x 100 |
|---|
| 1y Target Est: | 3.78 |
|---|
| Beta: | N/A |
|---|
| Next Earnings Date: | 28-Oct-13 |
|---|
| Day's Range: | 2.88 - 2.95 |
|---|
| 52wk Range: | 2.69 - 7.22 |
|---|
| Volume: | 2,836,601 |
|---|
| Avg Vol (3m): | 4,265,860 |
|---|
| Market Cap: | 448.93M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | N/A |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Dendreon: Looking For Spare Change In The Cushionsat Seeking Alpha(Sat, Sep 28)
- 4 Healthcare Stock Stories for Weekend Investment Wellnessat Wall St. Cheat Sheet(Fri, Sep 27)
- Ahead of the Bell: Dendreon Corp shares climbAP(Fri, Sep 27)
- Dendreon Corporation Announces Presentation of PROVENGE® (sipuleucel-T) Data at the 2013 European Cancer CongressBusiness Wire(Fri, Sep 27)
- One Person's Trash Is Another Person's Treasure Portfolioat Motley Fool(Fri, Sep 27)
- 5 Names With Significant Short Interest Declinesat Seeking Alpha(Thu, Sep 26)
- Don't Write Off This Lung Cancer Vaccine Just Yetat Motley Fool(Wed, Sep 25)
- Lightning Round: Ford, Five Below & Moreat CNBC(Mon, Sep 23)
- This Week in Biotechat Motley Fool(Sat, Sep 21)
- One Person's Trash Is Another Person's Treasure Portfolioat Motley Fool(Thu, Sep 19)
- DENDREON CORP Files SEC form 8-K, Other Events, Financial Statements and ExhibitsEDGAR Online(Thu, Sep 19)
- Pandora Raises Funds: What Company Is Next?at Seeking Alpha(Thu, Sep 19)
- September 27th Options Now Available For Dendreon (DNDN)at Forbes(Thu, Sep 19)
- Can an EU Approval Save This Dying Biotech?at Motley Fool(Thu, Sep 19)
- [$$] Less Down on Dendreonat Barrons.com(Thu, Sep 19)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 1.47 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -1.72 |
|---|
| Quarterly EPS Est
(Sep-13)
: | -0.42 |
|---|
| Mean Recommendation*: | 3.4 |
|---|
| PEG Ratio (5 yr expected): | -0.02 |
|---|
Business Summary
Dendreon Corporation, a biotechnology company, engages in the discovery, development, and commercialization of novel therapeutics to enhance cancer treatment options for patients.
View More